Phase I/II safety and efficacy study of image guided intratumoral CD40 agonistic monoclonal antibody APX005M in combination with systemic pembrolizumab in metastatic melanoma patients

被引：0
|
作者：
Johnson, Daniel Johnson H. [1 ]
Lecagoonporn, Srisuda [1 ]
Bernatchez, Chantale [1 ]
Haymaker, Cara [1 ]
Bentebibel, Salah [1 ]
Uemura, Marc [1 ]
Yee, Cassian [1 ]
Amaria, Rodabe [1 ]
Patel, Sapna [1 ]
Tawbi, Hussein [1 ]
Glitza, Isabella [1 ]
Davies, Michael A. [1 ]
Wong, Michael K. [1 ]
Hwu, Wen-Jen [1 ]
Hwu, Patrick [1 ]
Overwijk, Willem [1 ]
Diab, Adi [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2017年 / 5卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P230
引用
收藏
页数：1
相关论文
共 43 条
  • [21] Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma
    Bajor, David L.
    Mick, Rosemarie
    Riese, Matthew J.
    Huang, Alex C.
    Sullivan, Brendan
    Richman, Lee P.
    Torigian, Drew A.
    George, Sangeeth M.
    Stelekati, Erietta
    Chen, Fang
    Melenhorst, J. Joseph
    Lacey, Simon F.
    Xu, Xiaowei
    Wherry, E. John
    Gangadhar, Tara C.
    Amaravadi, Ravi K.
    Schuchter, Lynn M.
    Vonderheide, Robert H.
    ONCOIMMUNOLOGY, 2018, 7 (10):
  • [22] Early Pharmacodynamic Changes Measured Using RNA Sequencing of Peripheral Blood from Patients in a Phase I Study with Mitazalimab, a Potent CD40 Agonistic Monoclonal Antibody
    Andersson, Hampus
    Sobti, Aastha
    Jimenez, David Gomez
    de Coana, Yago Pico
    Ambarkhane, Sumeet Vijay
    Hagerbrand, Karin
    Smith, Karin Enell
    Lindstedt, Malin
    Ellmark, Peter
    CELLS, 2023, 12 (19)
  • [23] A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma
    Beatty, Gregory L.
    Torigian, Drew A.
    Chiorean, E. Gabriela
    Saboury, Babak
    Brothers, Alex
    Alavi, Abass
    Troxel, Andrea B.
    Sun, Weijing
    Teitelbaum, Ursina R.
    Vonderheide, Robert H.
    O'Dwyer, Peter J.
    CLINICAL CANCER RESEARCH, 2013, 19 (22) : 6286 - 6295
  • [24] Early safety and efficacy from a phase I open-label clinical study of LVGN7409 (CD40 agonist antibody) in patients with advanced or metastatic malignancies.
    Fu, Siqing
    Vandross, Andrae Lavon
    Hsu, Yi Hsin
    Shi, Naiyi
    Jiang, Lynn
    Su, Fusheng
    Wang, Jieyi
    Chan, C. Hubert
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [25] Phase 1b study of maintenance soluble beta-glucan (Odetiglucan) in combination with a CD40 agonistic monoclonal antibody (CDX-1140) in patients with metastatic pancreatic adenocarcinoma that had not progressed on first-line chemotherapy
    O'Hara, Mark H.
    Wattenberg, Max
    Garrido-Laguna, Ignacio
    O'Reilly, Eileen M.
    Yellin, Michael
    Keler, Tibor
    Gargano, Michele
    Niles, Nick
    Drees, Jeremy
    Bose, Nandita
    Beatty, Gregory L.
    CANCER RESEARCH, 2024, 84 (17)
  • [26] Phase I/II study of stereotactic body radiation therapy (SBRT) to metastatic lesions in the liver or lung in combination with monoclonal antibody to OX40 in patients with progressive metastatic breast cancer (mBC) after systemic therapy.
    Crittenden, Marka
    Conlin, Alison Katherine
    Moxon, Nicole
    Curti, Brendan D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [27] Randomized phase II study of the safety and efficacy of a human anti-αv integrin monoclonal antibody (CNTO 95) alone and in combination with dacarbazine in patients with stage IV metastatic melanoma: 12-month results
    Loquai, C.
    Pavlick, A.
    Lawson, D.
    Gutzmer, R.
    Richards, J.
    Gore, M. E.
    de Boer, C. J.
    Uhlar, C.
    Lang, Z.
    O'Day, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [28] Phase I/II study of the tumor-targeting human L19-IL2 monoclonal antibody-cytokine fusion protein in combination with DTIC in metastatic melanoma patients
    Garbe, C.
    Romanini, A.
    Spitaleri, G.
    Giovannoni, L.
    Zardi, L.
    Neri, D.
    Shaw, A.
    Menssen, H. D.
    deBraud, F.
    Eigentler, T. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [29] Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study
    Chuanliang Cui
    Yu Chen
    Zhiguo Luo
    Zhengyun Zou
    Yu Jiang
    Hongming Pan
    Qingxia Fan
    Jianfu Zhao
    Qing Xu
    Renbing Jiang
    Xuan Wang
    Taiyang Ma
    Zhen Guo
    Lu Si
    Zhihong Chi
    Xinan Sheng
    Yiwei Dou
    Qian Tan
    Di Wu
    Jun Guo
    BMC Cancer, 23
  • [30] Safety and efficacy of Pucotenlimab (HX008)-a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study
    Cui, Chuanliang
    Chen, Yu
    Luo, Zhiguo
    Zou, Zhengyun
    Jiang, Yu
    Pan, Hongming
    Fan, Qingxia
    Zhao, Jianfu
    Xu, Qing
    Jiang, Renbing
    Wang, Xuan
    Ma, Taiyang
    Guo, Zhen
    Si, Lu
    Chi, Zhihong
    Sheng, Xinan
    Dou, Yiwei
    Tan, Qian
    Wu, Di
    Guo, Jun
    BMC CANCER, 2023, 23 (01)
12345